Vitiligo
Conditions
Brief summary
The cohort included only major patients with non-segmental vitiligo and no other autoimmune or inflammatory associated diseases (except thyroiditis). Control subjects should have no autoimmune or inflammatory diseases. Patients and controls should not take treatment with corticosteroids or other potentially immunomodulatory therapies. Patients and controls are recruited in the Dermatology Department of the University Hospital of Nice and the Hospital of Fréjus. The investigators have already initiated the collection of tissues and blood from patients and control subjects and we have succeeded in isolating ILCs and NKs from a blood volume of 50ml. We were able to sort the ILC subpopulations. Early data suggest an increase in Natural Killer (NK) and Innate Lymphoïdes Cells 1 (ILC1) in the blood of vitiligo patients compared to control subjects. The investigators also managed to extract the melanocytes from the skin biopsies of the first patients and control subjects.
Detailed description
The investigators want study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
Interventions
To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
Sponsors
Study design
Eligibility
Inclusion criteria
vitiligo subjects : * patients in the cohort with non-segmental vitiligo * without other autoimmune or inflammatory diseases associated control subjects : * subject without autoimmune or inflammatory disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| study the presence and type of ILC and NK in the blood and skin | 1 day | Compare vitiligo patients to control subjects. |
| study the presence and type of ILC and NK in the skin | 1 day | Compare vitiligo patients to control subjects. |
Countries
France